Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review
S Chenchula, P Karunakaran… - Journal of medical …, 2022 - Wiley Online Library
Abstract Coronavirus disease 2019 (COVID‐19) is an ongoing pandemic, which affected
around 45 million confirmed cases of COVID‐19, including more than 6 million deaths …
around 45 million confirmed cases of COVID‐19, including more than 6 million deaths …
SARS‐CoV‐2 Omicron and its current known unknowns: A narrative review
TTB Le, T Vasanthakumaran… - Reviews in Medical …, 2023 - Wiley Online Library
The emergence of the SARS‐CoV‐2 Omicron variant (B. 1.1. 529) has created great global
distress. This variant of concern shows multiple sublineages, importantly B. 1.1. 529.1 (BA …
distress. This variant of concern shows multiple sublineages, importantly B. 1.1. 529.1 (BA …
Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination
SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the
circulation; however, it is currently unknown whether it elicits effective immune responses in …
circulation; however, it is currently unknown whether it elicits effective immune responses in …
Attenuated replication and pathogenicity of SARS-CoV-2 B. 1.1. 529 Omicron
Abstract The Omicron (B. 1.1. 529) variant of SARS-CoV-2 emerged in November 2021 and
is rapidly spreading among the human population. Although recent reports reveal that the …
is rapidly spreading among the human population. Although recent reports reveal that the …
Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters
The in vivo pathogenicity, transmissibility, and fitness of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) Omicron (B. 1.1. 529) variant are not well …
syndrome coronavirus 2 (SARS-CoV-2) Omicron (B. 1.1. 529) variant are not well …
Enhanced evasion of neutralizing antibody response by Omicron XBB. 1.5, CH. 1.1, and CA. 3.1 variants
P Qu, JN Faraone, JP Evans, YM Zheng, C Carlin… - Cell reports, 2023 - cell.com
Omicron subvariants continuingly challenge current vaccination strategies. Here, we
demonstrate nearly complete escape of the XBB. 1.5, CH. 1.1, and CA. 3.1 variants from …
demonstrate nearly complete escape of the XBB. 1.5, CH. 1.1, and CA. 3.1 variants from …
Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection
JP Evans, C Zeng, C Carlin, G Lozanski… - Science Translational …, 2022 - science.org
The waning efficacy of SARS-CoV-2 vaccines, combined with the continued emergence of
variants resistant to vaccine-induced immunity, has reignited debate over the need for …
variants resistant to vaccine-induced immunity, has reignited debate over the need for …
Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by …
Genetic variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
continue to dramatically alter the landscape of the coronavirus disease 2019 (COVID-19) …
continue to dramatically alter the landscape of the coronavirus disease 2019 (COVID-19) …
[HTML][HTML] Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA. 2.86 and FLip variants
Evolution of SARS-CoV-2 requires the reassessment of current vaccine measures. Here, we
characterized BA. 2.86 and XBB-derived variant FLip by investigating their neutralization …
characterized BA. 2.86 and XBB-derived variant FLip by investigating their neutralization …
Evasion of neutralizing antibody responses by the SARS-CoV-2 BA. 2.75 variant
Summary The newly emerged BA. 2.75 severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) variant contains 9 additional mutations in its spike (S) protein compared to …
(SARS-CoV-2) variant contains 9 additional mutations in its spike (S) protein compared to …